- Home
- GDEN vs JANX Comparison
GDEN vs JANX Comparison
Compare GDEN & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDEN | JANX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | 504 | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 763.2M | 790.3M |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GDEN | JANX |
|---|---|---|
| Price | $27.69 | $13.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $32.25 | ★ $53.60 |
| AVG Volume (30 Days) | 139.4K | ★ 784.8K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $634,911,000.00 | $10,000,000.00 |
| Revenue This Year | $5.70 | N/A |
| Revenue Next Year | $2.96 | $209.90 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.57 | $12.12 |
| 52 Week High | $32.74 | $35.34 |
Technical Indicators
Market Signals| Indicator | GDEN | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 39.60 | 51.39 |
| Support Level | $26.82 | $13.80 |
| Resistance Level | $27.95 | $14.46 |
| Average True Range (ATR) | 0.61 | 0.53 |
| MACD | -0.20 | 0.11 |
| Stochastic Oscillator | 21.82 | 64.55 |
Price Performance
Historical ComparisonAbout GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.